(b)(4).Type of investigation: historical data analysis - a five-year review of similar reported thrombosis/occlusive events relating to gelsoft branded grafts was completed, an occurence rate of (b)(4) (complaints v sales) was confirmed and no negative trend was detected analysis of production records - qc, manufacturing and physical test records of the base material were retrieved and reviewed and show that the batch was manufactured to design specification and all tests met acceptance criteria.Communication/interviews further information on event and its circumstances was requested from the reporting site (ct data) as well as clarification of the event/ device relationship.Analysis of data provided by user / third party - ct data from implant to date of event confirmed that the patient has had previous occlusive formations within this graft and within other devices that have been implanted (e.G.An insitu fevar device), in which the ca vessel stent is also occluded.Device not returned - the actual device involved in the adverse event will not be returned as it remains insitu within the patients anatomy.Investigation findings: no device problem found - no issue has been found on review of device history records of any issue with the manufacture of this device.Investigation conclusions: adverse event related to patient condition - no graft defect was detected during the ct data review with no visible kinking which may have affected flow.Thrombus was detected within an existing fevar device and the ca stent was occluded.The patient has a previous and on going arterial disease with peripheral arterial occlusive disease which is being treated with medications.Vascutek ltd.Considers this event as closed.Further action is not planned, however, the issue will be tracked and trended as part of the on-going complaints trending and reporting process and if an adverse trend develops action may be taken at that time.
|